Cell Therapeutics Should Consider Different Trial Design For Pixuvri, FDA's Pazdur Says

The odds were against Cell Therapeutics from the beginning of the Oncology Drugs Advisory Committee meeting, as FDA officials had concluded that the single, incomplete clinical trial did not provide enough evidence of efficacy.